Various methods of surgical resection may be employed and each of these has its own sets of risks and perioperative complications.
The benefits, risks and complications are discussed by the patient and surgical team before arriving at a well-informed decision. The method of surgical resection depends on the following features:[1][2][3]
The National Comprehensive Cancer Network (NCCN) has recommended certain guidelines on resectability of pancreatic neoplasms based on a statement passed by the American pancreatic association:[4][5][6][7][8]
Palliative therapy in patients with pancreatic cancer mainly involves the management of symptoms arising as a result of complications of surgery:[88][89][90][91][92][93][94][95]
↑Allen PJ, Kuk D, Castillo CF, Basturk O, Wolfgang CL, Cameron JL, Lillemoe KD, Ferrone CR, Morales-Oyarvide V, He J, Weiss MJ, Hruban RH, Gönen M, Klimstra DS, Mino-Kenudson M (2017). "Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma". Ann. Surg. 265 (1): 185–191. doi:10.1097/SLA.0000000000001763. PMID27163957.
↑Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP, Talamonti MS (2007). "Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database". Cancer. 110 (4): 738–44. doi:10.1002/cncr.22852. PMID17580363.
↑Al-Hawary MM, Francis IR, Chari ST, Fishman EK, Hough DM, Lu DS, Macari M, Megibow AJ, Miller FH, Mortele KJ, Merchant NB, Minter RM, Tamm EP, Sahani DV, Simeone DM (2014). "Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association". Radiology. 270 (1): 248–60. doi:10.1148/radiol.13131184. PMID24354378.
↑ 6.06.16.2Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, Mohile SG, Mumber M, Schulick R, Shapiro M, Urba S, Zeh HJ, Katz MH (2016). "Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline". J. Clin. Oncol. 34 (21): 2541–56. doi:10.1200/JCO.2016.67.5553. PMID27247221.
↑ 7.07.1Yamada S, Fujii T, Sugimoto H, Nomoto S, Takeda S, Kodera Y, Nakao A (2013). "Aggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines". Pancreas. 42 (6): 1004–10. doi:10.1097/MPA.0b013e31827b2d7c. PMID23532000.
↑Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, Javle MM, Eads JR, Allen P, Ko AH, Engebretson A, Herman JM, Strickler JH, Benson AB, Urba S, Yee NS (2016). "Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline". J. Clin. Oncol. 34 (22): 2654–68. doi:10.1200/JCO.2016.67.5561. PMID27247216.
↑Al-Haddad M, Martin JK, Nguyen J, Pungpapong S, Raimondo M, Woodward T, Kim G, Noh K, Wallace MB (2007). "Vascular resection and reconstruction for pancreatic malignancy: a single center survival study". J. Gastrointest. Surg. 11 (9): 1168–74. doi:10.1007/s11605-007-0216-x. PMID17632763.
↑Donahue TR, Isacoff WH, Hines OJ, Tomlinson JS, Farrell JJ, Bhat YM, Garon E, Clerkin B, Reber HA (2011). "Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery". Arch Surg. 146 (7): 836–43. doi:10.1001/archsurg.2011.152. PMID21768431.
↑Tseng JF, Raut CP, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Gomez HF, Sun CC, Crane CH, Wolff RA, Evans DB (2004). "Pancreaticoduodenectomy with vascular resection: margin status and survival duration". J. Gastrointest. Surg. 8 (8): 935–49, discussion 949–50. doi:10.1016/j.gassur.2004.09.046. PMID15585381.
↑Martin RC, Scoggins CR, Egnatashvili V, Staley CA, McMasters KM, Kooby DA (2009). "Arterial and venous resection for pancreatic adenocarcinoma: operative and long-term outcomes". Arch Surg. 144 (2): 154–9. doi:10.1001/archsurg.2008.547. PMID19221327.
↑Castleberry AW, White RR, De La Fuente SG, Clary BM, Blazer DG, McCann RL, Pappas TN, Tyler DS, Scarborough JE (2012). "The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American College of Surgeons National Surgical Quality Improvement Program database". Ann. Surg. Oncol. 19 (13): 4068–77. doi:10.1245/s10434-012-2585-y. PMID22932857.
↑Leach SD, Lee JE, Charnsangavej C, Cleary KR, Lowy AM, Fenoglio CJ, Pisters PW, Evans DB (1998). "Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head". Br J Surg. 85 (5): 611–7. doi:10.1046/j.1365-2168.1998.00641.x. PMID9635805.
↑Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N, Nakagawa N, Sueda T (2013). "Benefit of portal or superior mesenteric vein resection with adjuvant chemotherapy for patients with pancreatic head carcinoma". J Surg Oncol. 107 (4): 414–21. doi:10.1002/jso.23229. PMID22886567.
↑Ramacciato G, Mercantini P, Petrucciani N, Giaccaglia V, Nigri G, Ravaioli M, Cescon M, Cucchetti A, Del Gaudio M (2009). "Does portal-superior mesenteric vein invasion still indicate irresectability for pancreatic carcinoma?". Ann. Surg. Oncol. 16 (4): 817–25. doi:10.1245/s10434-008-0281-8. PMID19156463.
↑Mollberg N, Rahbari NN, Koch M, Hartwig W, Hoeger Y, Büchler MW, Weitz J (2011). "Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis". Ann. Surg. 254 (6): 882–93. doi:10.1097/SLA.0b013e31823ac299. PMID22064622.
↑ 19.019.1Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, Arnold D (2015). "Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up". Ann. Oncol. 26 Suppl 5: v56–68. doi:10.1093/annonc/mdv295. PMID26314780.
↑Seufferlein T, Bachet JB, Van Cutsem E, Rougier P (2012). "Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Ann. Oncol. 23 Suppl 7: vii33–40. doi:10.1093/annonc/mds224. PMID22997452.
↑Evans DB, George B, Tsai S (2015). "Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced-Definitions of Increasing Importance for the Optimal Delivery of Multimodality Therapy". Ann. Surg. Oncol. 22 (11): 3409–13. doi:10.1245/s10434-015-4649-2. PMID26122369.
↑Rombouts SJ, Vogel JA, van Santvoort HC, van Lienden KP, van Hillegersberg R, Busch OR, Besselink MG, Molenaar IQ (2015). "Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer". Br J Surg. 102 (3): 182–93. doi:10.1002/bjs.9716. PMID25524417.
↑Krzyzanowska MK, Weeks JC, Earle CC (2003). "Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness". J. Clin. Oncol. 21 (18): 3409–14. doi:10.1200/JCO.2003.03.007. PMID12972517.
↑Aristu J, Cañón R, Pardo F, Martínez-Monge R, Martin-Algarra S, Manuel Ordoñez J, Villafranca E, Moreno M, Cambeiro M, Azinovic I (2003). "Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer". Am. J. Clin. Oncol. 26 (1): 30–6. PMID12576921.
↑Turrini O, Viret F, Moureau-Zabotto L, Guiramand J, Moutardier V, Lelong B, Giovannini M, Delpero JR (2009). "Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma". Eur J Surg Oncol. 35 (12): 1306–11. doi:10.1016/j.ejso.2009.06.005. PMID19576722.
↑Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, Mohile SG, Mumber M, Schulick R, Shapiro M, Urba S, Zeh HJ, Katz M (2017). "Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update". J. Clin. Oncol. 35 (20): 2324–2328. doi:10.1200/JCO.2017.72.4948. PMID28398845. Vancouver style error: initials (help)
↑Gurusamy KS, Kumar S, Davidson BR, Fusai G (2014). "Resection versus other treatments for locally advanced pancreatic cancer". Cochrane Database Syst Rev (2): CD010244. doi:10.1002/14651858.CD010244.pub2. PMID24578248.
↑Doi R, Imamura M, Hosotani R, Imaizumi T, Hatori T, Takasaki K, Funakoshi A, Wakasugi H, Asano T, Hishinuma S, Ogata Y, Sunamura M, Yamaguchi K, Tanaka M, Takao S, Aikou T, Hirata K, Maguchi H, Aiura K, Aoki T, Kakita A, Sasaki M, Ozaki M, Matsusue S, Higashide S, Noda H, Ikeda S, Maetani S, Yoshida S (2008). "Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial". Surg. Today. 38 (11): 1021–8. doi:10.1007/s00595-007-3745-8. PMID18958561.
↑Lygidakis NJ, Singh G, Bardaxoglou E, Dedemadi G, Sgourakis G, Nestoridis J, Malliotakis A, Pedonomou M, Solomou EK, Safioleas M, Alamani M, Grigorakos L, Merikas EM (2004). "Mono-bloc total spleno-pancreaticoduodenectomy for pancreatic head carcinoma with portal-mesenteric venous invasion. A prospective randomized study". Hepatogastroenterology. 51 (56): 427–33. PMID15086174.
↑ 34.034.1Farnell MB, Pearson RK, Sarr MG, DiMagno EP, Burgart LJ, Dahl TR, Foster N, Sargent DJ (2005). "A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma". Surgery. 138 (4): 618–28, discussion 628–30. doi:10.1016/j.surg.2005.06.044. PMID16269290.
↑Balcom JH, Rattner DW, Warshaw AL, Chang Y, Fernandez-del Castillo C (2001). "Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization". Arch Surg. 136 (4): 391–8. PMID11296108.
↑Serrano PE, Cleary SP, Dhani N, Kim PT, Greig PD, Leung K, Moulton CA, Gallinger S, Wei AC (2015). "Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods". Ann. Surg. Oncol. 22 (4): 1160–7. doi:10.1245/s10434-014-4196-2. PMID25348784.
↑Sinn M, Striefler JK, Sinn BV, Sallmon D, Bischoff S, Stieler JM, Pelzer U, Bahra M, Neuhaus P, Dörken B, Denkert C, Riess H, Oettle H (2013). "Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study". J Surg Oncol. 108 (6): 398–402. doi:10.1002/jso.23409. PMID24038103.
↑Massucco P, Capussotti L, Magnino A, Sperti E, Gatti M, Muratore A, Sgotto E, Gabriele P, Aglietta M (2006). "Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival". Ann. Surg. Oncol. 13 (9): 1201–8. doi:10.1245/s10434-006-9032-x. PMID16955382.
↑Sun J, Yang Y, Wang X, Yu Z, Zhang T, Song J, Zhao H, Wen J, Du Y, Lau WY, Zhang Y (2014). "Meta-analysis of the efficacies of extended and standard pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas". World J Surg. 38 (10): 2708–15. doi:10.1007/s00268-014-2633-9. PMID24912627.
↑Millikan KW, Deziel DJ, Silverstein JC, Kanjo TM, Christein JD, Doolas A, Prinz RA (1999). "Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas". Am Surg. 65 (7): 618–23, discussion 623–4. PMID10399969.
↑van der Gaag NA, Rauws EA, van Eijck CH, Bruno MJ, van der Harst E, Kubben FJ, Gerritsen JJ, Greve JW, Gerhards MF, de Hingh IH, Klinkenbijl JH, Nio CY, de Castro SM, Busch OR, van Gulik TM, Bossuyt PM, Gouma DJ (2010). "Preoperative biliary drainage for cancer of the head of the pancreas". N. Engl. J. Med. 362 (2): 129–37. doi:10.1056/NEJMoa0903230. PMID20071702.
↑Geer RJ, Brennan MF (1993). "Prognostic indicators for survival after resection of pancreatic adenocarcinoma". Am. J. Surg. 165 (1): 68–72, discussion 72–3. PMID8380315.
↑Benassai G, Mastrorilli M, Quarto G, Cappiello A, Giani U, Mosella G (2000). "Survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas". Chir Ital. 52 (3): 263–70. PMID10932371.
↑Pellegrini CA, Heck CF, Raper S, Way LW (1989). "An analysis of the reduced morbidity and mortality rates after pancreaticoduodenectomy". Arch Surg. 124 (7): 778–81. PMID2742478.
↑Kneuertz PJ, Pitt HA, Bilimoria KY, Smiley JP, Cohen ME, Ko CY, Pawlik TM (2012). "Risk of morbidity and mortality following hepato-pancreato-biliary surgery". J. Gastrointest. Surg. 16 (9): 1727–35. doi:10.1007/s11605-012-1938-y. PMID22760965.
↑Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, Welch HG, Wennberg DE (2002). "Hospital volume and surgical mortality in the United States". N. Engl. J. Med. 346 (15): 1128–37. doi:10.1056/NEJMsa012337. PMID11948273.
↑Birkmeyer JD, Warshaw AL, Finlayson SR, Grove MR, Tosteson AN (1999). "Relationship between hospital volume and late survival after pancreaticoduodenectomy". Surgery. 126 (2): 178–83. PMID10455881.
↑Bilimoria KY, Talamonti MS, Sener SF, Bilimoria MM, Stewart AK, Winchester DP, Ko CY, Bentrem DJ (2008). "Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer". J. Am. Coll. Surg. 207 (4): 510–9. doi:10.1016/j.jamcollsurg.2008.04.033. PMID18926452.
↑Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL (2003). "Surgeon volume and operative mortality in the United States". N. Engl. J. Med. 349 (22): 2117–27. doi:10.1056/NEJMsa035205. PMID14645640.
↑Gooiker GA, van Gijn W, Wouters MW, Post PN, van de Velde CJ, Tollenaar RA (2011). "Systematic review and meta-analysis of the volume-outcome relationship in pancreatic surgery". Br J Surg. 98 (4): 485–94. doi:10.1002/bjs.7413. PMID21500187.
↑Limongelli P, Pai M, Bansi D, Thiallinagram A, Tait P, Jackson J, Habib NA, Williamson RC, Jiao LR (2007). "Correlation between preoperative biliary drainage, bile duct contamination, and postoperative outcomes for pancreatic surgery". Surgery. 142 (3): 313–8. doi:10.1016/j.surg.2007.04.022. PMID17723881.
↑Wente MN, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, Neoptolemos JP, Padbury RT, Sarr MG, Traverso LW, Yeo CJ, Büchler MW (2007). "Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS)". Surgery. 142 (5): 761–8. doi:10.1016/j.surg.2007.05.005. PMID17981197.
↑Tsao JI, Rossi RL, Lowell JA (1994). "Pylorus-preserving pancreatoduodenectomy. Is it an adequate cancer operation". Arch Surg. 129 (4): 405–12. PMID7908796.
↑Hüttner FJ, Fitzmaurice C, Schwarzer G, Seiler CM, Antes G, Büchler MW, Diener MK (2016). "Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma". Cochrane Database Syst Rev. 2: CD006053. doi:10.1002/14651858.CD006053.pub6. PMID26905229.
↑Sindelar WF (1989). "Clinical experience with regional pancreatectomy for adenocarcinoma of the pancreas". Arch Surg. 124 (1): 127–32. PMID2910241.
↑Riviere D, Gurusamy KS, Kooby DA, Vollmer CM, Besselink MG, Davidson BR, van Laarhoven CJ (2016). "Laparoscopic versus open distal pancreatectomy for pancreatic cancer". Cochrane Database Syst Rev. 4: CD011391. doi:10.1002/14651858.CD011391.pub2. PMID27043078.
↑Johnson CD, Schwall G, Flechtenmacher J, Trede M (1993). "Resection for adenocarcinoma of the body and tail of the pancreas". Br J Surg. 80 (9): 1177–9. PMID8402126.
↑Liu A, Carmichael KA, Schallom ME, Klinkenberg WD (2017). "Retrospective review of postoperative glycemic control in patients after distal pancreatectomy". Int J Surg. 41: 86–90. doi:10.1016/j.ijsu.2017.03.060. PMID28347869.
↑Strobel O, Brangs S, Hinz U, Pausch T, Hüttner FJ, Diener MK, Schneider L, Hackert T, Büchler MW (2017). "Incidence, risk factors and clinical implications of chyle leak after pancreatic surgery". Br J Surg. 104 (1): 108–117. doi:10.1002/bjs.10316. PMID27763684.
↑Müller MW, Friess H, Kleeff J, Dahmen R, Wagner M, Hinz U, Breisch-Girbig D, Ceyhan GO, Büchler MW (2007). "Is there still a role for total pancreatectomy?". Ann. Surg. 246 (6): 966–74, discussion 974–5. doi:10.1097/SLA.0b013e31815c2ca3. PMID18043098.
↑Karpoff HM, Klimstra DS, Brennan MF, Conlon KC (2001). "Results of total pancreatectomy for adenocarcinoma of the pancreas". Arch Surg. 136 (1): 44–7, discussion 48. PMID11146775.
↑Ryska M, Rudiš J (Fall 2016). "[Total pancreatectomy for pancreatic malignancy - from history to the present day]". Rozhl Chir (in Czech). 95 (10): 345–349. PMID27879138.CS1 maint: Unrecognized language (link)
↑Tol JA, Gouma DJ, Bassi C, Dervenis C, Montorsi M, Adham M, Andrén-Sandberg A, Asbun HJ, Bockhorn M, Büchler MW, Conlon KC, Fernández-Cruz L, Fingerhut A, Friess H, Hartwig W, Izbicki JR, Lillemoe KD, Milicevic MN, Neoptolemos JP, Shrikhande SV, Vollmer CM, Yeo CJ, Charnley RM (2014). "Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS)". Surgery. 156 (3): 591–600. doi:10.1016/j.surg.2014.06.016. PMID25061003.
↑Jang JY, Kang MJ, Heo JS, Choi SH, Choi DW, Park SJ, Han SS, Yoon DS, Yu HC, Kang KJ, Kim SG, Kim SW (2014). "A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer". Ann. Surg. 259 (4): 656–64. doi:10.1097/SLA.0000000000000384. PMID24368638.
↑Nimura Y, Nagino M, Takao S, Takada T, Miyazaki K, Kawarada Y, Miyagawa S, Yamaguchi A, Ishiyama S, Takeda Y, Sakoda K, Kinoshita T, Yasui K, Shimada H, Katoh H (2012). "Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial". J Hepatobiliary Pancreat Sci. 19 (3): 230–41. doi:10.1007/s00534-011-0466-6. PMID22038501.
↑Kang MJ, Jang JY, Chang YR, Kwon W, Jung W, Kim SW (2014). "Revisiting the concept of lymph node metastases of pancreatic head cancer: number of metastatic lymph nodes and lymph node ratio according to N stage". Ann. Surg. Oncol. 21 (5): 1545–51. doi:10.1245/s10434-013-3473-9. PMID24419758.
↑Pawlik TM, Gleisner AL, Cameron JL, Winter JM, Assumpcao L, Lillemoe KD, Wolfgang C, Hruban RH, Schulick RD, Yeo CJ, Choti MA (2007). "Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer". Surgery. 141 (5): 610–8. doi:10.1016/j.surg.2006.12.013. PMID17462460.
↑House MG, Gönen M, Jarnagin WR, D'Angelica M, DeMatteo RP, Fong Y, Brennan MF, Allen PJ (2007). "Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer". J. Gastrointest. Surg. 11 (11): 1549–55. doi:10.1007/s11605-007-0243-7. PMID17786531.
↑Bergquist JR, Puig CA, Shubert CR, Groeschl RT, Habermann EB, Kendrick ML, Nagorney DM, Smoot RL, Farnell MB, Truty MJ (2016). "Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study". J. Am. Coll. Surg. 223 (1): 52–65. doi:10.1016/j.jamcollsurg.2016.02.009. PMID27049786.
↑Mastenbroek TC, Kramp-Hendriks BJ, Kallewaard JW, Vonk JM (2017). "Multimodal intrathecal analgesia in refractory cancer pain". Scand J Pain. 14: 39–43. doi:10.1016/j.sjpain.2016.10.002. PMID28850428.
↑Schenker Y, Bahary N, Claxton R, Childers J, Chu E, Kavalieratos D, King L, Lembersky B, Tiver G, Arnold RM (2017). "A Pilot Trial of Early Specialty Palliative Care for Patients with Advanced Pancreatic Cancer: Challenges Encountered and Lessons Learned". J Palliat Med. doi:10.1089/jpm.2017.0113. PMID28772092.
↑Ouyang H, Ma W, Liu F, Yue Z, Fang M, Quan M, Pan Z (2017). "Factors influencing survival of patients with pancreatic adenocarcinoma and synchronous liver metastases receiving palliative care". Pancreatology. 17 (5): 773–781. doi:10.1016/j.pan.2017.07.002. PMID28734721.
↑Agarwal R, Epstein AS (2017). "Palliative care and advance care planning for pancreas and other cancers". Chin Clin Oncol. 6 (3): 32. doi:10.21037/cco.2017.06.16. PMID28705009.
↑Laquente B, Calsina-Berna A, Carmona-Bayonas A, Jiménez-Fonseca P, Peiró I, Carrato A (2017). "Supportive care in pancreatic ductal adenocarcinoma". Clin Transl Oncol. doi:10.1007/s12094-017-1682-6. PMID28612201.